Ipsogen has introduced the Mapquant Dx HER2 test which determines tumour HER2 status and guides Herceptin prescription for breast cancer.
The Mapquant Dx HER2 test was developed on the Mapquant Dx microarray diagnostic platform.
It accurately measures a set of HER2-amplified genes that correlate with HER2 protein expression.
The HER2 test provides reliable information for pathologists, oncologists and patients.
